Claire Page, a senior associate scientist in process development, working in a fume hood at Sonoma Biotherapeutics recently ... the floors of the building on Elliott Avenue, which will bring ...

Regulatory T cell-focused Sonoma Biotherapeutics has been following a slow and steady path ever since bringing in a whopping $265 million in a 2021 fundraising round, one of the largest of the year.

SOUTH SAN FRANCISCO, Calif. & SEATTLE, May 13, 2025--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg ...

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (T reg) therapies for ...

March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and ...

Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment Under ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the ...

nasdaq 100 euro stoxx 50 ftse-100 ...